Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Novel Agents Needed in MPNs Paradigm to Improve Outcomes

September 3rd 2020

Omar Alkharabsheh, MD, discusses the growing treatment options for patients with myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and myelofibrosis, and how available agents have not induced a biological change or shown improvement in disease outcomes.

Dr. Alkharabsheh on the Goals of Treatment in MPNs

September 1st 2020

Omar Alkharabsheh, MD, discusses the current goals of treatment in myeloproliferative neoplasms.

Dr. Verstovsek on the MANIFEST Trial With CPI-0610 in Myelofibrosis

August 29th 2020

Srdan Verstovsek, MD, PhD, discusses the phase 2 MANIFEST study, which examined CPI-0610 as an “add-on” to ruxolitinib in patients with myelofibrosis.

MPL Mutations Linked to Increased Risk of Myelofibrosis Transformation in Essential Thrombocythemia

August 26th 2020

The presence of MPL mutations in patients with essential thrombocythemia was found to be associated with an increased risk of myelofibrotic transformation.

Rigosertib Fails to Meet OS End Point in Higher-Risk MDS

August 24th 2020

Intravenous rigosertib did not meet the primary end point of significantly improved overall survival versus physician’s choice of therapy plus best supportive care in patients with higher-risk myelodysplastic syndromes.

Dr. Mesa on Accrual Considerations in MPN Clinical Trials

August 17th 2020

Ruben A. Mesa, MD, discusses accrual considerations in myeloproliferative neoplasms clinical trials.

TP53 Mutation Status Possesses Prognostic Implications in MDS

August 14th 2020

Patients with myelodysplastic syndromes who have biallelic TP53 have worse outcomes, such as treatment-resistant disease, rapid disease progression, and low overall survival, versus those with monoallelic mutations.

Pacritinib Pretreatment Demonstrates Intriguing Interim Findings in Myelofibrosis

August 14th 2020

Pretreatment with the investigational JAK2/FLT3 inhibitor pacritinib prior to allogeneic stem cell transplant was shown to be feasible and safe in patients with primary, post-polycythemia vera or post-essential thrombocythemia myelofibrosis.

Next-Generation Sequencing Shows Marked Potential for Diagnostic Improvements in MPNs

August 13th 2020

Patients with a suspected or diagnosed myeloproliferative neoplasm should undergo targeted next-generation sequencing versus sequential or allele specific testing to reduce the risk of identifying a false driver mutation or an excluded diagnosis of MPN.

Dr. Mesa on Developing Racially Inclusive Clinical Trials in MPNs

August 13th 2020

Ruben A. Mesa, MD, discusses the importance of developing racially inclusive clinical trials in myeloproliferative neoplasms.

Dr. Mascarenhas Discusses Ongoing Clinical Trials in Myelofibrosis

August 12th 2020

John O. Mascarenhas, MD, discusses ongoing clinical trials in myelofibrosis.

Mesa Sheds Light on Strategies to Combat Racial/Ethnic Disparities in Cancer Clinical Trials

August 11th 2020

Ruben Mesa, MD, discusses racial and ethnic disparities in cancer clinical trials and efforts that are being made to address these issues.

Dr. Mesa on Racial Disparities in MPN, MDS, and AML Clinical Trials

August 10th 2020

Ruben A. Mesa, MD, discusses racial disparities in clinical trials for patients with myeloproliferative neoplasms, myelodysplastic syndrome, and acute myeloid leukemia.

Dr. Hoffman on the Design of an Ongoing Trial Testing PTG-300 in Polycythemia Vera

August 7th 2020

Ronald Hoffman, MD, discusses the design of an ongoing phase 2 trial evaluating the first-in-class synthetic hepcidin mimetic PTG-300 in patients with polycythemia vera.

Dr. Mascarenhas on Approved and Emerging Treatment Options in Myelofibrosis

August 6th 2020

John O. Mascarenhas, MD, discusses approved and emerging treatment options in myelofibrosis.

Dr. Wang on Future Research With CAR T-Cell Therapy in MCL

August 5th 2020

Michael Wang, MD, discusses the importance of additional CAR T-cell therapy research in mantle cell lymphoma.

Dr. Mesa on Mitigating Racial Disparities in MPN Clinical Trials

August 5th 2020

Ruben A. Mesa, MD, discusses mitigating racial disparities in myeloproliferative neoplasm clinical trials.

Dr. Mesa on the Potential Utility of CAR T-Cell Therapy in MPNs

August 3rd 2020

Ruben A. Mesa, MD, discusses the potential utility of CAR T-cell therapy in myeloproliferative neoplasms.

FDA Grants Pevonedistat Breakthrough Status for Higher-Risk MDS

July 30th 2020

The FDA has granted breakthrough therapy designation to pevonedistat for the treatment of patients with higher-risk myelodysplastic syndromes.

First-in-Class LSD1 Inhibitor Elicits Clinical Activity in Advanced Myelofibrosis

July 24th 2020

Findings from a phase 2 study presented during the 2020 European Hematology Association Congress shed light on the first-in-class, investigational lysine-specific demethylase-1 inhibitor, bomedemstat, along with its promising clinical activity and tolerable safety profile as monotherapy in patients with advanced myelofibrosis.